Drug Trial Radar · NCT02143713
Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain
Last checked: Nov 19, 2026Latest source record: Jul 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
496
Actual
Start
May 27, 2014
Primary completion
Jun 22, 2016
Study completion May 23, 2017
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 21, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized study evaluating the continued safety and efficacy of elagolix in the management of moderate to severe endometriosis associated pain in adult pre-menopausal women who completed 6 months treatment in pivotal Study M12-671 (NCT01931670).
Conditions
- Endometriosis
Interventions
ElagolixDrug
Elagolix tablets administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Response for Dysmenorrhea at Month 6 Based on Daily AssessmentTime frame: Baseline (defined as baseline of Study M12-671 for participants who received elagolix in the pivotal study and baseline of the extension study M12-821 for participants who received placebo in the pivotal study) and Month 6
- Percentage of Participants With a Response for Non-menstrual Pelvic Pain at Month 6 Based on Daily AssessmentTime frame: Baseline (defined as baseline of Study M12-671 for participants who received elagolix in the pivotal study and baseline of the extension study M12-821 for participants who received placebo in the pivotal study) and Month 6
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.